糖尿病性腎症患者におけるカナグリフロジンの腎臓および心血管系への影響の評価

基本情報

NCT ID

NCT02065791

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

4,401

治験依頼者名

Janssen Research & Development, LLC

概要

The goal of this study is to assess whether canagliflozin has a renal and vascular protective effect in reducing the progression of renal impairment relative to placebo in participants with type 2 diabetes mellitus (T2DM), Stage 2 or 3 chronic kidney disease (CKD) and macroalbuminuria, who are receiving standard of care including a maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB).

対象疾患

介入

依頼者（Sponsor）